Page last updated: 2024-09-05

fiduxosin and tamsulosin

fiduxosin has been researched along with tamsulosin in 3 studies

Compound Research Comparison

Studies (fiduxosin)	Trials (fiduxosin)	Recent Studies (post-2010) (fiduxosin)	Studies (tamsulosin)	Trials (tamsulosin)	Recent Studies (post-2010) (tamsulosin)
14	3	5	1,460	468	693

Protein Interaction Comparison

Protein	Taxonomy	tamsulosin (IC50)
Alpha-1D adrenergic receptor	Homo sapiens (human)	0.0008
Alpha-1A adrenergic receptor	Homo sapiens (human)	0.0013
Alpha-1B adrenergic receptor	Homo sapiens (human)	0.0045
Alpha-1D adrenergic receptor	Mus musculus (house mouse)	0.0018
Alpha-1B adrenergic receptor	Mus musculus (house mouse)	0.0018
Alpha-1A adrenergic receptor	Mus musculus (house mouse)	0.0018

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Brune, ME; Hancock, AA; Katwala, SP; Kerwin, JF; Meyer, MD; Milicic, I; Williams, M; Witte, DG	1

Reviews

1 review(s) available for fiduxosin and tamsulosin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

2 other study(ies) available for fiduxosin and tamsulosin

Article	Year
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 300, Issue:2 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Heterocyclic Compounds, 3-Ring; Male; Phenylephrine; Prazosin; Prostate; Pyrimidinones; Regional Blood Flow; Sulfonamides; Tamsulosin; Urethra	2002

Article

Year

FDA-approved drug labeling for the study of drug-induced liver injury.

Drug discovery today, 2011, Volume: 16, Issue:15-16

Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011

Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs.

The Journal of pharmacology and experimental therapeutics, 2002, Volume: 300, Issue:2

Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Heterocyclic Compounds, 3-Ring; Male; Phenylephrine; Prazosin; Prostate; Pyrimidinones; Regional Blood Flow; Sulfonamides; Tamsulosin; Urethra

2002